

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON SEPTEMBER 16, 2022
AMENDMENTS TO THE ARTICLES OF ASSOCIATION
AND
RESIGNATION OF THE SUPERVISOR AND RE-ELECTION
OF THE CHAIRPERSON OF THE SUPERVISORY BOARD**

References are made to the notice and the circular (the “**Circular**”) of Jiangsu Recbio Technology Co., Ltd. (the “**Company**”) both dated September 1, 2022. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE EGM

The EGM was held at 10:00 a.m. on Friday, September 16, 2022 at Conference Room, 3/F, Building G29, Standard Plant, China Medical City Phase 6, Medical High-tech District, Taizhou City, Jiangsu Province, the PRC. All of the Directors attended the EGM.

As at the date of the EGM, the total number of issued Shares of the Company was 482,963,000, comprising 377,322,880 Domestic Shares, 12,000,000 Unlisted Foreign Shares and 93,640,120 H Shares, which was the total number of Shares entitling the holders to attend and vote on the resolutions proposed at the EGM. No Shareholders were required under the Listing Rules to abstain from voting on the resolutions. There were no Shares entitling the Shareholders to attend and abstain from voting in favor of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules. None of the Shareholders has stated his/her/its intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM. The convening of the EGM was in compliance with the relevant requirements of the PRC Company Law and the Articles of Association.

Shareholders and duly authorized proxies, holding a total of 360,995,880 Shares, representing approximately 74.75% of the total number of issued Shares, were present at the EGM. The resolutions proposed at the EGM were put to vote by way of poll.

The Board is pleased to announce that the following resolutions (special resolution marked with *) have been duly passed at the EGM and the details of the poll results are set out as follows:

RESOLUTIONS		NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the resolution on the 2022 H Share Incentive Scheme of the Company	360,948,880 (99.9870%)	47,000 (0.0130%)	0 (0%)
2.	To consider and approve the resolution on the authorization granted to the Board of Directors and its Delegates to deal with matters related to the 2022 H Share Incentive Scheme	360,948,880 (99.9870%)	47,000 (0.0130%)	0 (0%)
3.	* To consider and approve the resolution on the amendments to the Articles of Association	360,995,880 (100%)	0 (0%)	0 (0%)

As more than half of the votes were cast in favor of each of the resolutions numbered 1 and 2, these resolutions were duly passed as ordinary resolutions of the Company.

As more than two thirds of the votes were cast in favor of the resolution numbered 3, the resolution was duly passed as a special resolution of the Company.

SCRUTINEERS

The Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, two Shareholder representatives and one supervisor representative of the Company were appointed as the scrutineers for the purpose of vote-taking at the EGM.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In accordance with the poll results of the EGM, the Board hereby announces that the Articles of Association has been amended with effect from September 16, 2022. For the full text of the amended Articles of Association, please refer to the HKEXnews website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the website of the Company (www.recbio.cn).

RESIGNATION OF THE SUPERVISOR AND RE-ELECTION OF THE CHAIRPERSON OF THE SUPERVISORY BOARD

Reference is made to the announcement of the Company dated August 25, 2022 in relation to, among other things, Mr. Chen Gang ("Mr. Chen") has tendered his resignation as chairman and supervisor of the first session of the Supervisory Board of the Company due to changes in job assignment, which will take effect upon the approval of the amendments to the relevant provisions on the number of members of the Supervisory Board in the Articles of Association at the EGM. The Board hereby announces that Mr. Chen has resigned as chairman and supervisor of the Supervisory Board of the Company, with effect from September 16, 2022.

Mr. Chen has confirmed that he has no disagreement with the Company, the Board and the Supervisory Board and there are no other matters relating to his resignation that need to be brought to the attention of the Stock Exchange and the Shareholders.

On the same day, Ms. Qiao Weiwei (“**Ms. Qiao**”) was appointed as the chairwoman of the first session of the Supervisory Board of the Company. The biography of Ms. Qiao is set out in the 2021 annual report of the Company. Save as disclosed therein, the Board is not aware of other information of Ms. Qiao that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there are no other matters in relation to Ms. Qiao that need to be brought to the attention of the Shareholders.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. Liu Yong
Chairman

Jiangsu Province, the PRC, September 16, 2022

As at the date of this announcement, the Board comprises Dr. Liu Yong as the chairman of the Board and an executive Director, Dr. Chen Jianping and Mr. Li Bu as executive Directors, Dr. Hong Kunxue, Dr. Zhou Hongbin, Mr. Zhao Hui, Dr. Du Wei and Dr. Feng Tao as non-executive Directors, and Mr. Liang Guodong, Dr. Xia Lijun, Professor Gao Feng and Professor Yuen Ming Fai as independent non-executive Directors.